Company news

Tenaya Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

May 1, 2024

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 17, 2024

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

March 17, 2024

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

February 25, 2024

Tenaya Therapeutics Announces Pricing of Underwritten Offering

February 7, 2024

Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Tenaya Therapeutics to Participate at the 35th Annual Piper Sandler Healthcare Conference

November 20, 2023

Tenaya Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

November 7, 2023

Tenaya Therapeutics Announces FDA Clearance to Begin Clinical Testing of TN-401 Gene Therapy for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

October 25, 2023

Tenaya Therapeutics Presents Encouraging New Clinical and Preclinical Data from HDAC6 Inhibitor Program TN-301 for the Potential Treatment of Heart Failure with Preserved Ejection Fraction at the 2023 HFSA Annual Scientific Meeting

October 8, 2023

Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

October 4, 2023

Tenaya Therapeutics Publishes Preclinical Data in Circulation Highlighting the Clinical Potential of Cellular Reprogramming for Cardiac Regeneration

October 1, 2023

Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences

September 20, 2023

Tenaya Therapeutics to Participate at the 21st Annual Morgan Stanley Global Healthcare Conference

August 30, 2023

Tenaya Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

August 8, 2023

Tenaya Therapeutics to Participate at the 43rd Annual Canaccord Genuity Growth Conference

August 1, 2023

Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

May 9, 2023

Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting

May 2, 2023

Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201

May 1, 2023

Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

April 20, 2023

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 7, 2023

Tenaya Therapeutics to Participate in Upcoming Investor Conferences

February 6, 2023

Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones

January 8, 2023

Tenaya Therapeutics Appoints Amy Burroughs to Board of Directors

December 6, 2022

Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy

November 27, 2022

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 34th Annual Healthcare Conference

November 22, 2022

Tenaya Therapeutics Announces Closing of Public Offering

November 20, 2022

Tenaya Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

November 9, 2022

Tenaya Therapeutics to Present Preclincial Study Data from TN-301 Program at the American Heart Association Scientific Sessions 2022

November 3, 2022

Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress

October 3, 2022

Tenaya Therapeutics to Participate in Upcoming October Investor and Industry Conferences

September 28, 2022

Tenaya Therapeutics to Participate in Inaugural Hypertrophic Cardiomyopathy Medical Society’s 2022 Scientific Sessions

September 28, 2022

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences

September 5, 2022

Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction

September 5, 2022

Tenaya Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

August 9, 2022

Tenaya Therapeutics Publishes Preclinical Data in Science Translational Medicine Detailing Discovery of HDAC6 Inhibitor for Treatment of Heart Failure

July 5, 2022

Tenaya Therapeutics Launches Operations of New Genetic Medicines Manufacturing Center to Support the Development of Potentially First-In-Class Cardiovascular Therapeutics

June 15, 2022

Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference

May 19, 2022

Tenaya Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

May 10, 2022

Tenaya Therapeutics to Present Preclinical Data on Gene Therapy Programs and Platform Capabilities at the American Society of Gene and Cell Therapy 25th Annual Meeting

May 2, 2022

Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at Heart Rhythm 2022

April 27, 2022

Tenaya Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Updates

March 22, 2022

Tenaya Therapeutics Provides 2022 Business Updates

January 9, 2022

Tenaya Therapeutics Appoints Karah Parschauer, J.D., to Its Board of Directors and Joanna Auch as Senior Vice President of People and Culture

December 21, 2021

Tenaya Therapeutics Announces the Addition of Dr. June Lee to its Board of Directors

November 21, 2021

Tenaya Therapeutics to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference

November 18, 2021

Tenaya Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

November 9, 2021

Tenaya Therapeutics to Present Preclinical Data on Its Gene Therapy Programs at the ESGCT 28th Annual Congress

October 11, 2021

Tenaya Therapeutics to Participate in Upcoming Investor and Industry Conferences

September 29, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 10 decks. Every deck is listed under its year.